Soo Youn Lee
Research Subjects
Soo Youn Lee has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Darae Kim
Division of Cardiology, Department of Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
4 shared publications - Chi Young Shim
Severance Cardiovascular Hospital, Yonsei University College of Medicine
3 shared publications - Geu-Ru Hong
Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea
3 shared publications - Jong-Won Ha
Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea
3 shared publications - Kyung-Hee Kim
Department of Applied Chemistry, School of Science and Technology, Kookmin University, Seoul 02707, Republic of Korea
3 shared publications - Byung-Su Yoo
Division of Cardiology, Department of Internal Medicine, Yonsei University, Wonju College of Medicine, Wonju, Korea
2 shared publications
Latest Publications
- Open Access
- 22 July 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (15) , 1837
Transparent and Robust Artificial Intelligence-Driven Electrocardiogram Model for Left Ventricular Systolic Dysfunction
Background/Objectives: Heart failure (HF) is a growing global health burden, yet early detection remains challenging due to the limitations of traditional diagnostic tools such as electrocardiograms (ECGs). Recent advances in deep learning offer new opportunities to identify left ventricular systolic dysfunction (LVSD), a key indicator of HF, from ECG data. This study validates AiTiALVSD, our previously developed artificial intelligence (AI)-enabled ECG Software as a Medical Device, for its accuracy, transparency, and robustness in detecting LVSD. Methods: This retrospective single-center cohort study involved patients suspected of LVSD. The AiTiALVSD model, based on a deep learning algorithm, was evaluated against echocardiographic ejection fraction values. To enhance model transparency, the study employed Testing with Concept Activation Vectors (TCAV), clustering analysis, and robustness testing against ECG noise and lead reversals. Results: The study involved 688 participants and found AiTiALVSD to have a high diagnostic performance, with an AUROC of 0.919. There was a significant correlation between AiTiALVSD scores and left ventricular ejection fraction values, confirming the model’s predictive accuracy. TCAV analysis showed the model’s alignment with medical knowledge, establishing its clinical plausibility. Despite its robustness to ECG artifacts, there was a noted decrease in specificity in the presence of ECG noise. Conclusions: AiTiALVSD’s high diagnostic accuracy, transparency, and resilience to common ECG discrepancies underscore its potential for early LVSD detection in clinical settings. This study highlights the importance of transparency and robustness in AI-ECG, setting a new benchmark in cardiac care.
- 22 July 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (15) , 1837
Open AccessTransparent and Robust Artificial Intelligence-Driven Electrocardiogram Model for Left Ventricular Systolic Dysfunction
Background/Objectives: Heart failure (HF) is a growing global health burden, yet early detection remains challenging due to the limitations of traditional diagnostic tools such as electrocardiograms (ECGs). Recent advances in deep learning offer new opportunities to identify left ventricular systolic dysfunction (LVSD), a key indicator of HF, from ECG data. This study validates AiTiALVSD, our previously developed artificial intelligence (AI)-enabled ECG Software as a Medical Device, for its accuracy, transparency, and robustness in detecting LVSD. Methods: This retrospective single-center cohort study involved patients suspected of LVSD. The AiTiALVSD model, based on a deep learning algorithm, was evaluated against echocardiographic ejection fraction values. To enhance model transparency, the study employed Testing with Concept Activation Vectors (TCAV), clustering analysis, and robustness testing against ECG noise and lead reversals. Results: The study involved 688 participants and found AiTiALVSD to have a high diagnostic performance, with an AUROC of 0.919. There was a significant correlation between AiTiALVSD scores and left ventricular ejection fraction values, confirming the model’s predictive accuracy. TCAV analysis showed the model’s alignment with medical knowledge, establishing its clinical plausibility. Despite its robustness to ECG artifacts, there was a noted decrease in specificity in the presence of ECG noise. Conclusions: AiTiALVSD’s high diagnostic accuracy, transparency, and resilience to common ECG discrepancies underscore its potential for early LVSD detection in clinical settings. This study highlights the importance of transparency and robustness in AI-ECG, setting a new benchmark in cardiac care.
- Open Access
- 30 November 2023
- Published by Yeungnam University College of Medicine in Journal of Yeungnam Medical Science
- Vol. 40 (Suppl) , S98-S104
A rare pathogenic variant identified in a heart transplant recipient with hereditary transthyretin amyloidosis: a case report
Hereditary transthyretin (ATTRv) amyloidosis is a rare and complex genetic disorder that can lead to life-threatening cardiac amyloidosis and rapid disease progression. Early diagnosis and treatment with disease-modifying drugs can improve patient outcomes; however, heart transplantation may be necessary in some patients. We present the unique case of a 65-year-old Korean woman diagnosed with ATTRv amyloidosis after experiencing progressive neurological symptoms, followed by heart failure. Despite the absence of significant symptoms of heart failure, subsequent screening revealed cardiac amyloid infiltration, which caused left ventricular hypertrophy and rapid disease progression. The patient underwent successful heart transplantation, and subsequent genetic testing revealed a pathogenic variant, NM_000371.3:c.425T>C (p.Val142Ala), which affects both the nerves and heart and has not been previously reported in Korea. Our report underscores the potential benefits of heart transplantation in managing advanced ATTRv amyloidosis and emphasizes the need for continued research on the genetic heterogeneity of the disease. Clinicians should consider ATTRv amyloidosis in the differential diagnosis of patients presenting with neurological symptoms and heart failure, particularly in those with a family history of the disease.
- 30 November 2023
- Published by Yeungnam University College of Medicine in Journal of Yeungnam Medical Science
- Vol. 40 (Suppl) , S98-S104
Open AccessA rare pathogenic variant identified in a heart transplant recipient with hereditary transthyretin amyloidosis: a case report
Hereditary transthyretin (ATTRv) amyloidosis is a rare and complex genetic disorder that can lead to life-threatening cardiac amyloidosis and rapid disease progression. Early diagnosis and treatment with disease-modifying drugs can improve patient outcomes; however, heart transplantation may be necessary in some patients. We present the unique case of a 65-year-old Korean woman diagnosed with ATTRv amyloidosis after experiencing progressive neurological symptoms, followed by heart failure. Despite the absence of significant symptoms of heart failure, subsequent screening revealed cardiac amyloid infiltration, which caused left ventricular hypertrophy and rapid disease progression. The patient underwent successful heart transplantation, and subsequent genetic testing revealed a pathogenic variant, NM_000371.3:c.425T>C (p.Val142Ala), which affects both the nerves and heart and has not been previously reported in Korea. Our report underscores the potential benefits of heart transplantation in managing advanced ATTRv amyloidosis and emphasizes the need for continued research on the genetic heterogeneity of the disease. Clinicians should consider ATTRv amyloidosis in the differential diagnosis of patients presenting with neurological symptoms and heart failure, particularly in those with a family history of the disease.
- Open Access
- 1 January 2023
- Published by XMLink in International Journal of Heart Failure
- Vol. 5 (3) , 127-145
Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Management of the Underlying Etiologies and Comorbidities of Heart Failure
Park SM, et al. Int J Heart Fail. 2023 Jul;5:e17. https://doi.org/10.36628/ijhf.2023.0016
- 1 January 2023
- Published by XMLink in International Journal of Heart Failure
- Vol. 5 (3) , 127-145
Open AccessKorean Society of Heart Failure Guidelines for the Management of Heart Failure: Management of the Underlying Etiologies and Comorbidities of Heart Failure
Park SM, et al. Int J Heart Fail. 2023 Jul;5:e17. https://doi.org/10.36628/ijhf.2023.0016
- Open Access
- 1 January 2023
- Published by XMLink in Korean Circulation Journal
- Vol. 53 (7) , 425-451
Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Management of the Underlying Etiologies and Comorbidities of Heart Failure
Park SM, et al. Korean Circ J. 2023 Jul;53:e65. https://doi.org/10.4070/kcj.2023.0114
- 1 January 2023
- Published by XMLink in Korean Circulation Journal
- Vol. 53 (7) , 425-451
Open AccessKorean Society of Heart Failure Guidelines for the Management of Heart Failure: Management of the Underlying Etiologies and Comorbidities of Heart Failure
Park SM, et al. Korean Circ J. 2023 Jul;53:e65. https://doi.org/10.4070/kcj.2023.0114
- Open Access
- 8 March 2022
- Published by MDPI AG in Diagnostics
- Vol. 12 (3) , 654
Artificial Intelligence-Enhanced Smartwatch ECG for Heart Failure-Reduced Ejection Fraction Detection by Generating 12-Lead ECG
Background: We developed and validated an artificial intelligence (AI)-enabled smartwatch ECG to detect heart failure-reduced ejection fraction (HFrEF). Methods: This was a cohort study involving two hospitals (A and B). We developed the AI in two steps. First, we developed an AI model (ECGT2T) to synthesize ten-lead ECG from the asynchronized 2-lead ECG (Lead I and II). ECGT2T is a deep learning model based on a generative adversarial network, which translates source ECGs to reference ECGs by learning styles of the reference ECGs. For this, we included adult patients aged ≥18 years from hospital A with at least one digitally stored 12-lead ECG. Second, we developed an AI model to detect HFrEF using a 10 s 12-lead ECG. The AI model was based on convolutional neural network. For this, we included adult patients who underwent ECG and echocardiography within 14 days. To validate the AI, we included adult patients from hospital B who underwent two-lead smartwatch ECG and echocardiography on the same day. The AI model generates a 10 s 12-lead ECG from a two-lead smartwatch ECG using ECGT2T and detects HFrEF using the generated 12-lead ECG. Results: We included 137,673 patients with 458,745 ECGs and 38,643 patients with 88,900 ECGs from hospital A for developing the ECGT2T and HFrEF detection models, respectively. The area under the receiver operating characteristic curve of AI for detecting HFrEF using smartwatch ECG was 0.934 (95% confidence interval 0.913–0.955) with 755 patients from hospital B. The sensitivity, specificity, positive predictive value, and negative predictive value of AI were 0.897, 0.860, 0.258, and 0.994, respectively. Conclusions: An AI-enabled smartwatch 2-lead ECG could detect HFrEF with reasonable performance.
- 8 March 2022
- Published by MDPI AG in Diagnostics
- Vol. 12 (3) , 654
Open AccessArtificial Intelligence-Enhanced Smartwatch ECG for Heart Failure-Reduced Ejection Fraction Detection by Generating 12-Lead ECG
Background: We developed and validated an artificial intelligence (AI)-enabled smartwatch ECG to detect heart failure-reduced ejection fraction (HFrEF). Methods: This was a cohort study involving two hospitals (A and B). We developed the AI in two steps. First, we developed an AI model (ECGT2T) to synthesize ten-lead ECG from the asynchronized 2-lead ECG (Lead I and II). ECGT2T is a deep learning model based on a generative adversarial network, which translates source ECGs to reference ECGs by learning styles of the reference ECGs. For this, we included adult patients aged ≥18 years from hospital A with at least one digitally stored 12-lead ECG. Second, we developed an AI model to detect HFrEF using a 10 s 12-lead ECG. The AI model was based on convolutional neural network. For this, we included adult patients who underwent ECG and echocardiography within 14 days. To validate the AI, we included adult patients from hospital B who underwent two-lead smartwatch ECG and echocardiography on the same day. The AI model generates a 10 s 12-lead ECG from a two-lead smartwatch ECG using ECGT2T and detects HFrEF using the generated 12-lead ECG. Results: We included 137,673 patients with 458,745 ECGs and 38,643 patients with 88,900 ECGs from hospital A for developing the ECGT2T and HFrEF detection models, respectively. The area under the receiver operating characteristic curve of AI for detecting HFrEF using smartwatch ECG was 0.934 (95% confidence interval 0.913–0.955) with 755 patients from hospital B. The sensitivity, specificity, positive predictive value, and negative predictive value of AI were 0.897, 0.860, 0.258, and 0.994, respectively. Conclusions: An AI-enabled smartwatch 2-lead ECG could detect HFrEF with reasonable performance.
- Top Cited PapersOpen Access
- 9 April 2020
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 9 (7) , e014717
Deep Learning–Based Algorithm for Detecting Aortic Stenosis Using Electrocardiography
Background: Severe, symptomatic aortic stenosis ( AS ) is associated with poor prognoses. However, early detection of AS is difficult because of the long asymptomatic period experienced by many patients, during which screening tools are ineffective. The aim of this study was to develop and validate a deep learning–based algorithm, combining a multilayer perceptron and convolutional neural network, for detecting significant AS using ECGs. Methods and Results: This retrospective cohort study included adult patients who had undergone both ECG and echocardiography. A deep learning–based algorithm was developed using 39 371 ECG s. Internal validation of the algorithm was performed with 6453 ECG s from one hospital, and external validation was performed with 10 865 ECG s from another hospital. The end point was significant AS (beyond moderate). We used demographic information, features, and 500‐Hz, 12‐lead ECG raw data as predictive variables. In addition, we identified which region had the most significant effect on the decision‐making of the algorithm using a sensitivity map. During internal and external validation, the areas under the receiver operating characteristic curve of the deep learning–based algorithm using 12‐lead ECG for detecting significant AS were 0.884 (95% CI, 0.880–0.887) and 0.861 (95% CI, 0.858–0.863), respectively; those using a single‐lead ECG signal were 0.845 (95% CI, 0.841–0.848) and 0.821 (95% CI, 0.816–0.825), respectively. The sensitivity map showed the algorithm focused on the T wave of the precordial lead to determine the presence of significant AS . Conclusions: The deep learning–based algorithm demonstrated high accuracy for significant AS detection using both 12‐lead and single‐lead ECG s.
- 9 April 2020
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 9 (7) , e014717
Top Cited PapersOpen AccessDeep Learning–Based Algorithm for Detecting Aortic Stenosis Using Electrocardiography
Background: Severe, symptomatic aortic stenosis ( AS ) is associated with poor prognoses. However, early detection of AS is difficult because of the long asymptomatic period experienced by many patients, during which screening tools are ineffective. The aim of this study was to develop and validate a deep learning–based algorithm, combining a multilayer perceptron and convolutional neural network, for detecting significant AS using ECGs. Methods and Results: This retrospective cohort study included adult patients who had undergone both ECG and echocardiography. A deep learning–based algorithm was developed using 39 371 ECG s. Internal validation of the algorithm was performed with 6453 ECG s from one hospital, and external validation was performed with 10 865 ECG s from another hospital. The end point was significant AS (beyond moderate). We used demographic information, features, and 500‐Hz, 12‐lead ECG raw data as predictive variables. In addition, we identified which region had the most significant effect on the decision‐making of the algorithm using a sensitivity map. During internal and external validation, the areas under the receiver operating characteristic curve of the deep learning–based algorithm using 12‐lead ECG for detecting significant AS were 0.884 (95% CI, 0.880–0.887) and 0.861 (95% CI, 0.858–0.863), respectively; those using a single‐lead ECG signal were 0.845 (95% CI, 0.841–0.848) and 0.821 (95% CI, 0.816–0.825), respectively. The sensitivity map showed the algorithm focused on the T wave of the precordial lead to determine the presence of significant AS . Conclusions: The deep learning–based algorithm demonstrated high accuracy for significant AS detection using both 12‐lead and single‐lead ECG s.
- Open Access
- 8 August 2019
- Published by SAGE Publications in The International Journal of Artificial Organs
- Vol. 43 (1) , 37-44
Complications of veno-arterial extracorporeal membrane oxygenation for refractory cardiogenic shock or cardiac arrest
The frequency of using veno-arterial extracorporeal membrane oxygenation increased, especially in patients with refractory cardiogenic shock or cardiac arrest. However, data of complications of veno-arterial extracorporeal membrane oxygenation are lacking. This study sought to investigate the incidence of veno-arterial extracorporeal membrane oxygenation complications for acute myocardial infarction patients with refractory cardiogenic shock or cardiac arrest and its relationship with patient survival. This study included 151 consecutive patients who underwent veno-arterial extracorporeal membrane oxygenation between 2006 and 2018 at a single referral center. We divided the patients into those who survived for 30 days after veno-arterial extracorporeal membrane oxygenation (n = 57, 38%; group 1) and those who died within 30 days after veno-arterial extracorporeal membrane oxygenation support (n = 94, 62%; group 2). The major adverse clinical events associated with veno-arterial extracorporeal membrane oxygenation were defined as first occurrence of infection, major bleeding, and stroke. Adverse clinical events associated with veno-arterial extracorporeal membrane oxygenation occurred in 34 (59.6%) and 56 (59.6%) patients in groups 1 and 2, respectively. Group 2 had more patients who underwent new renal replacement therapy (21.1% vs 37.2%, p = 0.037). After multivariable analysis, cardiac arrest was independently associated with 30-day mortality (odds ratio = 3.6; 95% confidence interval = 1.7–7.63; p = 0.001). After excluding patients who died within 48 h after undergoing veno-arterial extracorporeal membrane oxygenation, new renal replacement therapy (odds ratio = 4.47; 95% confidence interval = 1.58–12.61; p = 0.005) and major adverse clinical events (odds ratio = 2.66; 95% confidence interval = 1.01–7.03; p = 0.049) were independently associated with 30-day mortality. Although veno-arterial extracorporeal membrane oxygenation can improve the survival, it is associated with morbidity. Therefore, risk–benefit analysis for veno-arterial extracorporeal membrane oxygenation and prevention of complications are important to improve prognosis.
- 8 August 2019
- Published by SAGE Publications in The International Journal of Artificial Organs
- Vol. 43 (1) , 37-44
Open AccessComplications of veno-arterial extracorporeal membrane oxygenation for refractory cardiogenic shock or cardiac arrest
The frequency of using veno-arterial extracorporeal membrane oxygenation increased, especially in patients with refractory cardiogenic shock or cardiac arrest. However, data of complications of veno-arterial extracorporeal membrane oxygenation are lacking. This study sought to investigate the incidence of veno-arterial extracorporeal membrane oxygenation complications for acute myocardial infarction patients with refractory cardiogenic shock or cardiac arrest and its relationship with patient survival. This study included 151 consecutive patients who underwent veno-arterial extracorporeal membrane oxygenation between 2006 and 2018 at a single referral center. We divided the patients into those who survived for 30 days after veno-arterial extracorporeal membrane oxygenation (n = 57, 38%; group 1) and those who died within 30 days after veno-arterial extracorporeal membrane oxygenation support (n = 94, 62%; group 2). The major adverse clinical events associated with veno-arterial extracorporeal membrane oxygenation were defined as first occurrence of infection, major bleeding, and stroke. Adverse clinical events associated with veno-arterial extracorporeal membrane oxygenation occurred in 34 (59.6%) and 56 (59.6%) patients in groups 1 and 2, respectively. Group 2 had more patients who underwent new renal replacement therapy (21.1% vs 37.2%, p = 0.037). After multivariable analysis, cardiac arrest was independently associated with 30-day mortality (odds ratio = 3.6; 95% confidence interval = 1.7–7.63; p = 0.001). After excluding patients who died within 48 h after undergoing veno-arterial extracorporeal membrane oxygenation, new renal replacement therapy (odds ratio = 4.47; 95% confidence interval = 1.58–12.61; p = 0.005) and major adverse clinical events (odds ratio = 2.66; 95% confidence interval = 1.01–7.03; p = 0.049) were independently associated with 30-day mortality. Although veno-arterial extracorporeal membrane oxygenation can improve the survival, it is associated with morbidity. Therefore, risk–benefit analysis for veno-arterial extracorporeal membrane oxygenation and prevention of complications are important to improve prognosis.
- Open Access
- 1 January 2019
- Published by XMLink in Yonsei Medical Journal
- Vol. 60 (9) , 816-823
Prevalence, Characteristics, and Clinical Significance of Concomitant Cardiomyopathies in Subjects with Bicuspid Aortic Valves
The present study aimed to investigate the prevalence, characteristics, and clinical significance of concomitant specific cardiomyopathies in subjects with bicuspid aortic valves (BAVs). A total of 1186 adults with BAV (850 males, mean age 56±14 years) at a single tertiary center were comprehensively reviewed. Left ventricular non-compaction, hypertrophic cardiomyopathy, and idiopathic dilated cardiomyopathy were confirmed when patients fulfilled current clinical and echocardiographic criteria. Clinical and echocardiographic characteristics, including comorbidities, heart failure presentation, BAV morphology, function, and aorta phenotypes, in BAV subjects with or without specific cardiomyopathies were compared. Overall, 67 subjects (5.6%) had concomitant cardiomyopathies: 40 (3.4%) patients with left ventricular non-compaction, 17 (1.4%) with hypertrophic cardiomyopathy, and 10 (0.8%) with dilated cardiomyopathy. BAV subjects with hypertrophic cardiomyopathy had higher prevalences of diabetes mellitus and heart failure with preserved ejection fraction, and tended to have type 0 phenotype, while BAV subjects with dilated cardiomyopathy showed higher prevalences of chronic kidney disease and heart failure with reduced ejection fraction. BAV subjects with left ventricular non-compaction were significantly younger and predominantly male, and had greater BAV dysfunction and a higher prevalence of normal aorta shape. In multiple regression analysis, cardiomyopathy was independently associated with heart failure (odds ratio 2.795, 95% confidential interval 1.603-4.873, p<0.001) after controlling for confounding factors. Concomitant cardiomyopathies were observed in 5.6% of subjects with BAV. A few different clinical and echocardiographic characteristics were found. The presence of cardiomyopathy was independently associated with heart failure.
- 1 January 2019
- Published by XMLink in Yonsei Medical Journal
- Vol. 60 (9) , 816-823
Open AccessPrevalence, Characteristics, and Clinical Significance of Concomitant Cardiomyopathies in Subjects with Bicuspid Aortic Valves
The present study aimed to investigate the prevalence, characteristics, and clinical significance of concomitant specific cardiomyopathies in subjects with bicuspid aortic valves (BAVs). A total of 1186 adults with BAV (850 males, mean age 56±14 years) at a single tertiary center were comprehensively reviewed. Left ventricular non-compaction, hypertrophic cardiomyopathy, and idiopathic dilated cardiomyopathy were confirmed when patients fulfilled current clinical and echocardiographic criteria. Clinical and echocardiographic characteristics, including comorbidities, heart failure presentation, BAV morphology, function, and aorta phenotypes, in BAV subjects with or without specific cardiomyopathies were compared. Overall, 67 subjects (5.6%) had concomitant cardiomyopathies: 40 (3.4%) patients with left ventricular non-compaction, 17 (1.4%) with hypertrophic cardiomyopathy, and 10 (0.8%) with dilated cardiomyopathy. BAV subjects with hypertrophic cardiomyopathy had higher prevalences of diabetes mellitus and heart failure with preserved ejection fraction, and tended to have type 0 phenotype, while BAV subjects with dilated cardiomyopathy showed higher prevalences of chronic kidney disease and heart failure with reduced ejection fraction. BAV subjects with left ventricular non-compaction were significantly younger and predominantly male, and had greater BAV dysfunction and a higher prevalence of normal aorta shape. In multiple regression analysis, cardiomyopathy was independently associated with heart failure (odds ratio 2.795, 95% confidential interval 1.603-4.873, p<0.001) after controlling for confounding factors. Concomitant cardiomyopathies were observed in 5.6% of subjects with BAV. A few different clinical and echocardiographic characteristics were found. The presence of cardiomyopathy was independently associated with heart failure.
- Open Access
Prevalence, Characteristics, and Clinical Significance of Concomitant Cardiomyopathies in Subjects with Bicuspid Aortic Valve
Background: In this study, the prevalence, characteristics, and clinical significance of concomitant specific cardiomyopathies (CMs) were investigated in subjects with bicuspid aortic valve (BAV). Methods: We retrospectively evaluated 1,186 adults with BAV (850 males, mean age 56 ± 14 years). Left ventricular noncompaction (LVNC), hypertrophic CM (HCM), and idiopathic dilated CM (DCM) were diagnosed when patients fulfilled current clinical and echocardiographic criteria. Clinical and echocardiographic characteristics including comorbidities, heart failure presentation, BAV morphology, function, and aorta phenotypes in BAV subjects with or without specific CM were compared. Results: Overall, 67 subjects (5.6 %) had concomitant CMs: 40 (3.4%) patients with LVNC, 17 (1.4%) with HCM, and 10 (0.8%) with DCM. BAV subjects with HCM had a higher prevalence of diabetes mellitus, heart failure with preserved ejection fraction (HFPEF), and tended to have type 0 phenotype, while BAV subjects with DCM showed a higher prevalence of chronic kidney disease and heart failure with reduced ejection fraction (HFREF). BAV subjects with LVNC were significantly younger, predominantly male, and had greater BAV dysfunction and a higher prevalence of normal aorta shape. In multiple regression analysis, presence of CM was independently associated with heart failure (odds ratio (OR) 2.866, 95% confidential interval (CI) 1.652–4.974, p < 0.001) even after controlling confounding factors. Conclusion: Concomitant CMs were observed in 5.6% of subjects with BAV. A few clinical and echocardiographic characteristics including comorbidities, heart failure presentation, BAV morphology, function, and presence of aortopathy were found. The presence of CM was independently associated with heart failure.
Open AccessPrevalence, Characteristics, and Clinical Significance of Concomitant Cardiomyopathies in Subjects with Bicuspid Aortic Valve
Background: In this study, the prevalence, characteristics, and clinical significance of concomitant specific cardiomyopathies (CMs) were investigated in subjects with bicuspid aortic valve (BAV). Methods: We retrospectively evaluated 1,186 adults with BAV (850 males, mean age 56 ± 14 years). Left ventricular noncompaction (LVNC), hypertrophic CM (HCM), and idiopathic dilated CM (DCM) were diagnosed when patients fulfilled current clinical and echocardiographic criteria. Clinical and echocardiographic characteristics including comorbidities, heart failure presentation, BAV morphology, function, and aorta phenotypes in BAV subjects with or without specific CM were compared. Results: Overall, 67 subjects (5.6 %) had concomitant CMs: 40 (3.4%) patients with LVNC, 17 (1.4%) with HCM, and 10 (0.8%) with DCM. BAV subjects with HCM had a higher prevalence of diabetes mellitus, heart failure with preserved ejection fraction (HFPEF), and tended to have type 0 phenotype, while BAV subjects with DCM showed a higher prevalence of chronic kidney disease and heart failure with reduced ejection fraction (HFREF). BAV subjects with LVNC were significantly younger, predominantly male, and had greater BAV dysfunction and a higher prevalence of normal aorta shape. In multiple regression analysis, presence of CM was independently associated with heart failure (odds ratio (OR) 2.866, 95% confidential interval (CI) 1.652–4.974, p < 0.001) even after controlling confounding factors. Conclusion: Concomitant CMs were observed in 5.6% of subjects with BAV. A few clinical and echocardiographic characteristics including comorbidities, heart failure presentation, BAV morphology, function, and presence of aortopathy were found. The presence of CM was independently associated with heart failure.
- 5 May 2018
- Published by Elsevier in Journal of Cardiology
- Vol. 72 (5) , 385-392
Adverse effects of left ventricular electrical dyssynchrony on cardiac reverse remodeling and prognosis after aortic valve surgery
- 5 May 2018
- Published by Elsevier in Journal of Cardiology
- Vol. 72 (5) , 385-392
Adverse effects of left ventricular electrical dyssynchrony on cardiac reverse remodeling and prognosis after aortic valve surgery